Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 801–900 of 1,000
The Editor's Roundtable: Hypertriglyceridemia
Friedewald, V. E., Ballantyne, C. M., Bays, H. E., & Jones, P. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.07.033 · Cited by 2
[Treat to target in rheumatoid arthritis].
Casado, G. C., & Alba, P. B. (2010) · PubMed · Cited by 2
Panretinal Photocoagulation for Diabetic Retinopathy
Zhang, Z.-Y., Hoffman, M. R., & Zhang, X. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113677 · Cited by 2
A systems engineering approach to coronary heart disease
Mathews, M. J. (2015) · Cited by 2
Risk Stratification According to Insulin Type: Reply
Cosmi, F., Staszewsky, L. I., McMurray, J. J. V., & Latini, R. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1218 · Cited by 2
Oh, G. C., Ki, Y., Park, K. W., Han, K., & Kim, H.-S. (2021) · Research Square · doi:10.21203/rs.3.rs-666003/v1 · Cited by 2
“The bene�t of tight glucose control on macrovascular or cardiovascular complications have been investigated in several previous trials [11, 12].”
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes
Boussageon, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61673-1 · Cited by 2
Fu, L., Zhou, Y., Sun, J., Zhu, Z., Xing, Z., Zhou, S., Wang, Y., & Tai, S. (2021) · Research Square · doi:10.21203/rs.3.rs-829355/v1 · Cited by 3
Hypoglycemie bij diabetes: relevant voor het cardiovasculaire risico en de cognitie?
Kooy, A. (2011) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-011-0016-5 · Cited by 2
DIABETES MANAGEMENT AND CURRENT PROSPECTS FOR SELF-MONITORING OF BLOOD GLUCOSE
Валерьевна, Г. Е., & Petunina, N. A. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-17-21 · Cited by 3
VITAMINS. PREVENTION AND TREATMENT OF COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS
Podachina, S. V. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-95-98 · Cited by 1
Shao, H., Laxy, M., Gregg, E. W., Albright, A. L., & Zhang, P. (2020) · Value in Health · doi:10.1016/j.jval.2020.09.010 · Cited by 1
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
You, Q.-Y., Xu, B., & Zhuge, F. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01151-7 · Cited by 1
Vihari, J., Sriteja, N., Sahu, S., Das, C., Sahoo, A. K., Swain, B., Vardhan, M. V., Jasthi, L. B., Elika, M., & Thammineni, R. (2023) · Medicine India · doi:10.25259/medindia_7_2022 · Cited by 3
Deng, S., Hu, X., & Zhang, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104120 · Cited by 1
Liu, M., Pei, J., Hu, X., & Wang, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328252 · Cited by 1
“None of the studies (such as the ACCORD study [24], the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study [37], and the Veterans Administration Diabetes Trial (VADT) [38]) designed to examine intensive glucose management have yielded positive…”
Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
Mohan, V., Makkar, B. M., Saboo, B., Jagadisha, A., Chawla, M. S., Deshpande, N., Goyal, V. K., & Kapoor, R. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_50_25 · Cited by 3
Liu, H., Wang, K., Ren, Y., Hu, X., Li, M., Wang, T., Xu, M., Lu, J., Bi, Y., & Xu, Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02877-7 · Cited by 1
“…was a randomized, double 2 × 2 factorial design study that evaluated the effects of intensive glycemic control, intensive blood pressure control, and combined fenofibrate plus statin treatment on the prevention of cardiovascular disease (CVD) in people with type 2 diabetes mellitus (T2DM) [23].”
Schaschinger, T., Munzinger, R., Niederegger, T., Brandt, J., Marcela, F. O., Knoedler, L., Rendenbach, C., Heiland, M., Matar, D. Y., Egloff, C., et al. (2026) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003962 · Cited by 1
Spécificité des accidents vasculaires cérébraux chez les diabétiques
Mechtouff, L., & Nighoghossian, N. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30141-3 · Cited by 1
Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
Ioacără, S., Guja, C., Reghina, A. D., Martin, S. C., Sîrbu, A. M., & Fica, S. V. (2015) · Journal of Diabetes Research · doi:10.1155/2015/962346 · Cited by 1
The Role of Supervised Exercise Therapy in Peripheral Arterial Obstructive Disease
Fokkenrood, H. J., Lauret, G.-J., Scheltinga, M. R., Hendriks, H. J. M., de, R. A., & Teijink, J. A. W. (2012) · InTech eBooks · doi:10.5772/51466 · Cited by 1
“44) after 5-year related with aggressive glucose lowering(20).”
BackgroundUnfavorable outcome of aggressive lowering of high blood pressure. Case report
Kuperczkó, D., Csécsei, P., Komáromy, H., Szapáry, L. B., & Fehér, G. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.30011 · Cited by 1
Comparative Effectiveness Research in Practice and Policy for Radiation Oncology
Lawrence, W. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.09.001 · Cited by 1
Hyperglycemia and survival rate in Asian patients with Acute Coronary Syndrome
Sin, H. Y. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0354-0 · Cited by 1
“This study result challenges the reports from the ACCORD study, which showed that intensive therapeutic approach of targeting HbA1C level below 6 % in patients with high risk of CVD and long standing DM is not recommended due to higher mortality (Gerstelin et al. 2011; Johnston et al. 2011; Kosiborod et al. 2009; Wien…”
BackgroundResultMistry, M., Lister, N., Andrews, C., Geransar, P., & Sinclair, A. J. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411421500 · Cited by 1
Aye, M. (2013) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000123 · Cited by 1
“However, even though early studies with fibrate therapy seemed to be beneficial, the ACCORD and others studies showed that combination therapy with statins and fibrates had no additional benefit over statins alone [23-30].”
ResultAktuelle kardiovaskuläre Outcome-Studien bei Diabetes
Kahles, F., & Marx, N. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0061-1 · Cited by 1
Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?
Forst, T. M. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0259-x · Cited by 1
Prediction of Global Cardiovascular Risk in Hypertension
Wilson, P. W. F. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00016-8 · Cited by 1
Assessment, types, and etiologies of vision loss in primary care settings
Alnahdi, A. T., Alobaid, A. A., Alajmi, A. K., Majed, A. S. A., Alkhars, A. F., Alsayyar, M. A., Althani, H. A., Almansour, A. J., Alsaadi, K. A., Aljaloud, N. A., et al. (2021) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20214081 · Cited by 1
“However, it was also reported that it is not clear about the effects of these favorable effects on older patients because, in these patients, tight glycemic control might induce hypoglycemia and increase the risk of mortality.(32,33) Accordingly, a target range of hemoglobin A1C of 8.”
BackgroundPowell, L. H., Kaufmann, P. G., & Freedland, K. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-39330-4_9 · Cited by 1
Seufert, J., Dänschel, I., Gölz, S., Haller, N., Kulzer, B., Tan, S., Schnell, O., Wiesner, T., & Kroeger, J. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2305-9093 · Cited by 1
“Obwohl die therapeutische Träg-heit das Ergebnis mehrerer Faktoren darstellt [61, 62, 63, 64], ist bekannt, dass insbesondere die Angst vor Hypoglykämien die Therapieeskalation verlangsamt [65, 66, 67].”
Bhosle, D. S., Chandekar, B., & Shelke, S. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0925 · Cited by 1
Sano, Y., Jin, R., Yoshioka, H., Nakazato, Y., Sato, H., & Hisaka, A. (2025) · Clinical and Translational Science · doi:10.1111/cts.70351 · Cited by 2
“The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial included more than 10,000 patients with type 2 diabetes and extensively examined whether intensive therapy targeting blood glucose, blood pressure, and lipids contributed to reducing cardiovascular risk [17–21].”
Cardiovascular Biomarker Assessment Across Glycemic Status
Li, D., & Tang, W. H. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00021-1 · Cited by 1
ADVANCE‐ON : further support for intensive glucose control in type 2 diabetes
Fisher, M. (2015) · Practical Diabetes · doi:10.1002/pdi.1912 · Cited by 3
Objectifs glycémiques dans la prise en charge du diabète de type 2
Bordier, L., & Bauduceau, B. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.02.052 · Cited by 1
“Toutefois, la mortalité globale est restée plus élevée dans le groupe initialement intensif lors d’un suivi supplémentaire de 17 mois permettant d’atteindre les cinq ans prévus au début de l’étude [8].”
BackgroundWhy OSA may be Regarded as the Real Hidden Killer in Diabetes
Tatti, P. (2014) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/1/1/00102 · Cited by 1
“Rather the benefit of this intervention versus a reduction of cholesterol or of blood pressure ranks very low [2,3] and under certain circumstances may even be definitely harmful [4].”
BackgroundA critical and evidence based glance at some of the major publications in Critical Care in 2011
Afshari, A. (2012) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2012.03.001 · Cited by 1
Lands, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-215-5_2 · Cited by 1
Hammersley, M. S., Rayman, G. A., Winocour, P. H., Weston, C. F. M., Birkhead, J. S., & On Behalf Of The Titan-ACS Steering Group (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.041 · Cited by 1
Cardiovascular Autonomic Neuropathy: Risk Factor or Risk Indicator
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_9 · Cited by 1
Özdemir, A. T., Aral, H., Erdenen, F., Özdemir, R. B. Ö., Emecen, Ö., Güvenen, G., & Müderrisoğlu, C. (2015) · Medical Science and Discovery · doi:10.17546/msd.91056 · Cited by 1
Wierzbicki, A. S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12072 · Cited by 1
Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment
Burns, C., & Sirisena, I. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_34-1 · Cited by 1
The Treatment of Diabetes after an Acute Ischemic Stroke
Biessels, G. J., & Kappelle, L. J. (2012) · US Endocrinology · doi:10.17925/use.2012.08.02.88 · Cited by 1
“Reasons for the higher mortality in the intensive therapy group remained unclear.(31) In a meta-analysis including 34,533 patients with type 2 diabetes no beneficial effects of tight glycaemic control versus standard glycaemic control could be demonstrated on stroke rates during a mean treatment period of five years (…”
BackgroundSpecial Problems in Caring for Patients on Peritoneal Dialysis
Heimbürger, O. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7657-4_12 · Cited by 1
Mancia, G., & Fagard, R. H. (2013) · Cited by 1
There really is no such thing as mild diabetes: a new perspective on an old idea
Baxter, M., & Hudson, R. D. A. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.113 · Cited by 1
Neue Antidiabetika und kardiovaskuläre Outcome-Studien
Seufert, J., & Laubner, K. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-121159 · Cited by 1
“Im Gegenteil, eine erhöhte Gesamt- und kardiovaskuläre Mortalität bei intensiv behandelten Patienten hat zu einem vorzeitigen Abbruch der ACCORD-Studie geführt.”
BackgroundL’éducation thérapeutique du patient diabétique et de son entourage vue par l’urgentiste
Lapostolle, F., Hamdi, N., Saona, H. L., Tepper, S., Akodad, H., & Adnet, F. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30104-9 · Cited by 1
Marahrens, L., Röck, D., Ziemssen, T., Kern, R., Ziemssen, F., & Fritsche, A. (2017) · Diabetes aktuell · doi:10.1055/s-0043-120327 · Cited by 5
“Nach der Veröffentlichung der ACCORD1Studie wurde für die Therapieziele des Typ-2-Diabetes ein Paradigmenwechsel eingeläutet [4]: Anstelle einer allgemeingültigen schematischen Absenkung des HbA1c-Wertes trat das Konzept einer individualisierten Therapie [5].”
BackgroundStratégie thérapeutique dans le traitement du diabète de type 2
Bauduceau, B., & Bordier, L. (2018) · Time to knit · doi:10.1016/s1155-1941(18)82762-7 · Cited by 1
Diabetes management gains: teaching old dogs new tricks
Sattar, N. A. (2019) · Diabetic Medicine · doi:10.1111/dme.14068 · Cited by 1
Adikusuma, W., & Nopitasari, B. L. (2019) · Journal of Young Pharmacists · doi:10.5530/jyp.2019.11.59 · Cited by 1
Kondratieva, D. S., Afanasiev, S. A., Будникова, О. В., Ворожцова, И. Н., Джаманович, А. Ш., & Shipulin, V. V. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2020-35-1-133-141 · Cited by 1
Modern Strategies to Save Sight in Diabetes.
Taylor, S. C., & Rajagopal, R. (2016) · Europe PMC (PubMed Central) · Cited by 1
More and more elderly diabetics: toward evidence-based deprescribing?
Micheli, A. D. (2018) · The Journal of AMD · doi:10.36171/jamd18.21.1.02 · Cited by 1
Kondratieva, D. S., Afanasiev, S. A., Будникова, О. В., Ворожцова, И. Н., Akhmedov, S. D., & Kozlov, B. N. (2021) · Diabetes Mellitus · doi:10.14341/dm12484 · Cited by 1
Metabolic syndrome and kidney disease
Kramer, H., & Joshi, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00028-8 · Cited by 1
Metabolic and endocrine diseases - is our approach always rational?
Brunerová, L., Urbanová, J., & Brož, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.107 · Cited by 1
Assessing the Practice (Know-Do) Gap
Fahim, C., & Straus, S. E. (2022) · Springer Publishing Company eBooks · doi:10.1891/9780826186935.0002 · Cited by 1
A retrospective study of diabetes treatment in older adults: what should we AIM for?
Çiğiloğlu, A., Efendioğlu, E. M., & Öztürk, Z. A. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2090175 · Cited by 1
“management of older adults with DM [27,28].”
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
Murphy, E., Cooney, M. T., & McEvoy, J. W. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_2 · Cited by 1
Rajput, R., Saini, S., Rajput, S., & Upadhyay, P. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_350_22 · Cited by 1
Kurt, B., & Kahles, F. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01109-1 · Cited by 1
Біомаркери та фактори ризику серцево-судинних уражень у хворих на цукровий діабет типу 2
Prystupiuk, O. (2013) · Likarska sprava · doi:10.31640/ls-2013-1-08 · Cited by 1
Managing the Complications of Diabetes
Shankarnarayan, S. H. (2012) · doi:10.1007/978-1-908517-81-4_6 · Cited by 1
Medical Nutrition Therapy for Diabetes: Prioritizing Recommendations Based on Evidence
Franz, M. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-894-8_6 · Cited by 1
Vedin, O. (2015) · Uppsala University Publications (Uppsala University) · Cited by 1
Weiner, D. E., & Winkelmayer, W. C. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.12.003 · Cited by 1
Coronary Artery Disease Screening Using Coronary Computed Tomography Angiography—Reply
Muhlestein, J. B., LAPPE, D. L., & Anderson, J. L. (2015) · JAMA · doi:10.1001/jama.2015.1435 · Cited by 1
Koh, K. K. (2016) · Circulation · doi:10.1161/circulationaha.116.025739 · Cited by 1
Challenges in Choosing a Medication for Type 2 Diabetes
Rodríguez‐Gutiérrez, R., Salcido‐Montenegro, A., Elizondo-Plazas, A., & González‐González, J. G. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0166 · Cited by 1
“Yet, in meta-analysis and some primary studies, there is a 15% relative-risk reduction of nonfatal myocardial infarctions.(3,6,14,15) Despite this, after a single study reported an increased cardiovascular risk with tight glycemic control (i.”
Association Between Glycemic Control and Incident Stroke ― Overview From an Epidemiologic Study ―
Hirata, T., & Okamura, T. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0422 · Cited by 1
Crutzen, S. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192818811 · Cited by 1
Sandoval, D. A., Lamos, E. M., Younk, L. M., Hedrington, M. S., & Davis, S. N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.03833-2 · Cited by 1
Uncovering Heart Failure in Type 2 Diabetes
Winter, L. J. M. B.-D. (2015) · Utrecht University Repository (Utrecht University) · doi:10.13140/rg.2.1.1508.7448 · Cited by 1
Primary stroke prevention and community education.
Vecchione, M. (2011) · PubMed
Bariatric Surgery on Type 2 Diabetes Mellitus Patients in Japan
Mori, J., Sato, Y., Ishii, H., & Komatsu, M. (2011) · 信州医学雑誌 · doi:10.11441/shinshumedj.59.273
Diabetes mellitus tipo 2: enfoque de su riesgo cardiovascular
Sánchez, A. E. (2014) · 16 de abril/Revista 16 de abril · Cited by 4
Bariatric Surgery on Obese Type 2 Diabetes Patients
Mori, J.-I., Sato, Y., & Komatsu, M. (2012) · InTech eBooks · doi:10.5772/33002
Diabetes Control and Hypoglycemia
Norwood, P. C., & Fogel, A. (2011) · InTech eBooks · doi:10.5772/23614
The Epidemiology of Macrovascular Complications of Diabetes in Finland 1992-2002
Winell, K. (2013) · Helda - University of Helsinki Institutional Repository · Cited by 2
Glycemic and blood-pressure control—lower is not better
Ruilope, L. M. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.34
Risk Stratification in Clinical Practice
Mendys, P., Joodi, G., & Simpson, R. J. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch38
Prescribing antidiabetic drugs for patients with renal dysfunction
Wilding, J. P. H., Kirby, M. G., & Evans, M. (2011) · Prescriber · doi:10.1002/psb.815
Complicaciones macrovasculares del paciente diabético
Escribano, F. M., la Orden, J. M., & Divisón, J. A. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70420-1
Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
Charbonnel, B. H. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.008
HTA et diabète : nouveaux niveaux de preuves et prise en charge
Chamontin, B., & Bouhanick, B. (2011) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(11)70287-5
Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes
Bellows, O. K., Hunter, E. L., & McAdam-Marx, C. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s1664 · Cited by 1
Control glucémico y mortalidad en el diabético tipo 1
Díaz, M. S. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2015.01.006
Utilización de prácticas inefectivas en atención primaria: opinión de los profesionales
Bustillo, L. D., Villar, J., Ruíz, S. C., Lahoz, F. J., & Remón, C. A. (2014) · Revista de Calidad Asistencial · doi:10.1016/j.cali.2014.04.003
Insights from the extended follow-up of the ACCORD trial
Zoungas, S., & Woodward, M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.65
Thukunthla, S., & Belalcazar, L. M. (2013) · Diabetes Care · doi:10.2337/dc12-2244
Lim, S. K., & Rutter, M. K. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0208-y
“7 years increased the 5-year mortality but reduced the 5year rate for nonfatal myocardial infarction [2].”
InfluentialTargeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
Yeboah, J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.057
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.